Breaking Finance News

A statement released earlier today by Canaccord Genuity about Vernalis PLC (LON:VER) raises the target price to 88.00GBX

In a report released on 9/29/2016 Canaccord Genuity increased the stock price target of Vernalis PLC (LON:VER) from 84.00GBX to 88.00GBX indicating a possible upside of 1.17%.

Previously on Thursday September 22, 2016, Panmure Gordon reported on Vernalis PLC (LON:VER) held steady the target price at 76.00GBX. At the time, this indicated a possible upside of 0.71%.

Yesterday Vernalis PLC (LON:VER) traded 3.70% higher at 40.63GBX. The company’s 50-day moving average is 43.63GBX and its 200-day moving average is 45.70GBX. The last closing price is down -8.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 256,354 shares of the stock traded hands, down from an average trading volume of 257,856

See Chart Below

Vernalis PLC (LON:VER)

Vernalis PLC has a 52 week low of 31.00GBX and a 52 week high of 79.00GBX The company’s market cap is currently 0 GBX.

In addition to Canaccord Genuity reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is 83.60GBX with 2 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Vernalis PLC (LON:VER)

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.